A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS)
|
Meeting/ Workshop
|
ASPR, FDA
|
NIAID
|
2018
|
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT)
|
Research Initiative
|
FDA
|
NIDA
|
2011
|
|
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Therapeutics Working Group
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ASPR
|
NIAID
|
2020
|
|
Accelerating COVID-19 Therapeutic Interventions and Vaccines-1: Immune Modulators (ACTIV-1)
|
Research Initiative
|
FDA, ASPR
|
|
2020
|
|
Accelerating COVID-19 Therapeutic Interventions and Vaccines-6: Outpatient Repurposed Drugs (ACTIV-6)
|
Research Initiative
|
CDC, FDA, ASPR
|
NIAID, NHLBI
|
2021
|
|
Accelerating Medicines Partnership (AMP)
|
Other
|
FDA
|
NIA, NIDDK, NIAMS, NINDS, NIMH
|
2014
|
|
Accelerating Medicines Partnership Schizophrenia (AMP SCZ)
|
Research Initiative
|
FDA
|
|
2020
|
|
AccessGUDID
|
Resource Development
|
FDA, GDM
|
|
2015
|
|
Adjuvant Working Group
|
Committee, Advisory Group, or Work Group
|
BARDA, FDA, ASPR
|
NCI, NIAID
|
2013
|
|
Advanced Anticonvulsant System Interagency Product Team
|
Committee, Advisory Group, or Work Group
|
FDA, OS
|
NINDS
|
2011
|
|
Advanced Viral Detection Technology IG (AVDTIG)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2018
|
|
Advancing American Kidney Health Initiative
|
Research Initiative
|
CDC, CMS, FDA, ASPE, ASPR, HRSA, IHS, OCR
|
NIEHS
|
2019
|
|
Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NHLBI
|
2003
|
|
Advisory Committee on Heritable Disorders in Newborns and Children
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA
|
NHGRI, NHLBI, NICHD, NIDDK, NLM
|
2014
|
|
Advisory Council on Blood Stem Cell Transplantation (ACBSCT) of the U.S. Department of Health and Human Services (HHS)
|
Committee, Advisory Group, or Work Group
|
CDC, CMS, FDA, HRSA
|
NHLBI
|
2008
|
|
Agency Priority Goals Maternal Health
|
Committee, Advisory Group, or Work Group
|
HRSA, NIH, ASPE, CDC, CMS, FDA, OASH, ACF, OGA, AHRQ, ACL
|
OD/ DPCPSI/ ORWH, NICHD, OD/ IMOD, OD/ DPCPSI/ OEPR
|
|
|
American Academy of Pediatrics (AAP) Committee on Drugs
|
Committee, Advisory Group, or Work Group
|
FDA
|
NICHD
|
|
|
American Academy of Pediatrics (AAP) Committee on Nutrition
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
|
|
American Academy of Pediatrics (AAP) Section on Obesity
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
|
|
American College of Obstetricians and Gynecologists (ACOG) Patient Education Review Panel
|
Committee, Advisory Group, or Work Group
|
FDA
|
NICHD
|
|
|
American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
|
|
AMP Bespoke Gene Therapy Program/Bespoke Gene Therapy Consortium (BGTC)
|
Research Initiative
|
FDA
|
NCATS, NHLBI, NIMH, NINDS
|
2019
|
|
Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION)
|
Research Initiative
|
FDA
|
NCATS, NCI, NIAAA, NIDA, NINDS
|
2011
|
|
Ancillary Swab Study to PREVENT-19 trial: Swab your Nose Inside to Find inFection (SNIFF)
|
Research Initiative
|
ASPR, CDC, FDA
|
|
2021
|
|
Antibody Interest Group (ABIG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NHLBI, NIAID, NIDCR, NIDDK
|
2010
|
|
Antimicrobial Drugs Advisory Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIAID
|
2007
|
|
Arthritis Advisory Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIAID
|
2017
|
|
Assay subgroup for SARS-CoV-2
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, BARDA, FDA
|
NIAID
|
2020
|
|
Autoimmune Diseases Coordinating Committee
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA
|
CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR
|
1998
|
|
Behavioral Health Coordinating Council (BHCC) Children and Youth Behavioral Health Subcommittee
|
Committee, Advisory Group, or Work Group
|
ACF, CMS, ACL, AHRQ, FDA, IHS, ASPE, CDC, OASH
|
NICHD, NIMH, NIDA
|
2021
|
|
Behavioral Health Coordinating Council (BHCC) Performance Measures, Data, and Evaluation Subcommittee (MDE)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ASA, ASPE, CDC, CMS, FDA, IHS, NIH, ONC, SAMHSA
|
NIDA, NIMH
|
2021
|
|
Bench to Bedside: Integrating Sex and Gender to Improve Human Health
|
Resource Development
|
FDA
|
|
2017
|
|
Best Pharmaceuticals for Children Act (BPCA) Data Monitoring Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NHLBI, NICHD
|
2009
|
|
Best Pharmaceuticals for Children Act (BPCA) Research Oversight Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
NICHD, NHLBI, NCI
|
|
|
Biodefense Coordination Team (BCT)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
OD/ OSP
|
2019
|
|
Biodosimetry Trans-NIH Working Group and Special Journal Issue
|
Committee, Advisory Group, or Work Group
|
ASPR, FDA
|
|
2019
|
|
Biomarkers of Radiation Injury Meeting
|
Meeting/ Workshop
|
ASPR, FDA
|
NIAID
|
2019
|
|
Blood Products Advisory Committee
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NHLBI
|
2011
|
|
Blood, Organ, and Tissue Senior Executive Council (BOTSEC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, OS
|
CC, NHLBI,
|
2012
|
|
Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NICHD
|
|
|
Botanical Safety Consortium
|
Research Initiative
|
FDA
|
NCCIH
|
2019
|
|
Brain Research through Advancing Innovative Neurotechnologies Initiative (BRAIN Initiative)
|
Research Initiative
|
FDA
|
NCCIH, NEI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIMH, NINDS, OD/ DPCPSI/ OBSSR
|
2014
|
|
BRIDG Standard Development
|
Research Initiative
|
FDA
|
|
2015
|
|
Bridge to Artificial Intelligence (Bridge2AI)
|
Research Initiative
|
FDA
|
NLM, NEI, NHGRI, NCCIH, NIBIB, NICHD, NCATS, NIMH, NIMHD, NIAID, NCI, NIAMS, NINDS, NIDA, NIA, NIGMS, FIC, OD/ DPCPSI/ OBSSR, OD/ AoU, OD/ DPCPSI/ ODSS
|
2021
|
|
Canadian - U.S. Dietary Reference Intakes Working Group
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, OASH
|
NIDDK, OD/ DPCPSI
|
2005
|
|
Cancer Diagnostic Devices Interagency Task Force (CD2) - MOU among NCI, FDA, HRSA
|
Committee, Advisory Group, or Work Group
|
FDA, HRSA
|
|
2021
|
|
CCDI Molecular Target Platform
|
Resource Development
|
FDA
|
|
2021
|
|
Cervical screening guidelines
|
Resource Development
|
CDC, HRSA, FDA
|
|
2019
|
|
Characterize Emerging HIV Strains from Blood Donors and Patients
|
Resource Development
|
FDA
|
NIAID
|
2009
|
|
Clinical and Translational Research Course for PhD Students
|
Training Initiative
|
FDA
|
CC, NCATS, NCI, NHLBI, NIAID, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NINDS
|
2012
|
|
Clinical and Translational Serology Task Force (CTTF)
|
Resource Development
|
CDC, FDA, ASPR
|
NCI, NIAID
|
2021
|
|
Clinical Investigator Interagency Working Group for the Development of Antiviral Influenza Therapeutics
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2009
|
|
Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs
|
Meeting/ Workshop
|
FDA
|
NIAID
|
2020
|
|
Collaborative Use Repurposing Engine ID (CURE ID)
|
Research Initiative
|
FDA
|
NCATS
|
2013
|
|
Combating Antibiotic Resistant Bacteria (CARB)
|
Resource Development
|
CDC, FDA
|
NHGRI, NIAID
|
2015
|
|
Computational Toxicology for NIH Medications Discovery
|
Research Initiative
|
FDA
|
NIDA
|
2000
|
|
Computer-aided Diagnosis for Radiology Images
|
Research Initiative
|
FDA
|
|
2004
|
|
Countering Biothreats IPC on Promoting and Protecting the Bioeconomy
|
Committee, Advisory Group, or Work Group
|
FDA, OS
|
OD/ OSP
|
2019
|
|
Countering Biothreats sub-IPC on Promoting and Protecting the Bioeconomy
|
Committee, Advisory Group, or Work Group
|
FDA, OS
|
OD/ OSP
|
2019
|
|
Countermeasures Against Chemical Threats (CounterACT) Research Network (CounterACT Research Network)
|
Research Initiative
|
CDC, FDA, OS
|
NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS, NINDS, NLM
|
2006
|
|
COVID-19 Therapeutics Interagency Working Group
|
Committee, Advisory Group, or Work Group
|
FDA, CDC
|
NIAID
|
2020
|
|
CTAC Ad hoc Strategic Planning Working Group (CTAC SPWG)
|
Committee, Advisory Group, or Work Group
|
FDA, CMS
|
NCI
|
2019
|
|
Cytokine Interest Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
NEI, NHGRI, NIA, NIAID, NIAMS, NICHD, NIDCR, NIDCD
|
2007
|
|
DailyMed
|
Resource Development
|
FDA
|
|
2005
|
|
Department of Health and Human Services (DHHS) Medical Claims Review Panel
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
|
1990
|
|
Department of Health and Human Services AAPI Memorandum Workgroup
|
Meeting/ Workshop
|
AHRQ, FDA, OASH, CDC, ASFR, ASPE, CMS
|
|
2021
|
|
Development of New Approach Methodologies to Reduce Animal Use in Toxicity Testing -SBIR/STTR Town Hall Meeting
|
Meeting/ Workshop
|
FDA
|
|
2020
|
|
Diabetes Mellitus Interagency Coordinating Committee (DMICC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OASH
|
NHGRI
|
1974
|
|
Diagnostics and Disease Management Tools for Use in Underserved Populations: An NHLBI Research & Implementation Workshop
|
Meeting/ Workshop
|
AHRQ, CMS, CDC, FDA, OASH, HRSA, IHS
|
NCATS, NIMHD, NIBIB
|
2021
|
|
Diet-induced Hypomethylation in Preneoplastic Liver/Genetics ; Epigenetics of Susceptibility to Non-Alcoholic Fatty Liver Disease
|
Research Initiative
|
FDA
|
|
2004
|
|
Digestive Diseases Interagency Coordinating Committee (DDICC)
|
Committee, Advisory Group, or Work Group
|
CDC, CMS, FDA
|
NCI, NIBIB
|
1985
|
|
Digital Quantitation of Plasma Cells in Marrow Biopsies
|
Research Initiative
|
FDA
|
|
2011
|
|
Drug Data Interagency Working Group (Data IWG)
|
Committee, Advisory Group, or Work Group
|
FDA, ASPE, CDC, SAMHSA
|
NIDA
|
|
|
Drug Induced Liver Injury Network (DILIN)
|
Resource Development
|
FDA
|
NCI
|
2003
|
|
Ebola Clinical Research Response in West Africa (Guinea, Liberia)
|
Research Initiative
|
CDC, FDA
|
NIAID
|
2014
|
|
eCare Plan for People with Multiple Chronic Conditions Project
|
Committee, Advisory Group, or Work Group
|
AHRQ, CMS, FDA, HRSA, ASPE, ACL
|
NCI, NIA, NIDDK, NLM
|
2019
|
|
End-stage Renal Disease Collaboration
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NIBIB
|
2016
|
|
Endocrinologic and Metabolic Drugs Advisory Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIAID
|
|
|
eRA Federal Shared Services (eRA)
|
Resource Development
|
AHRQ, FDA, SAMHSA
|
OD/ OER
|
2016
|
|
Establishment of representative examination and dose repository for patients undergoing interventional fluoroscopic procedures
|
Research Initiative
|
FDA
|
|
2021
|
|
Extracellular Ribonucleic Acid (RNA) Communication
|
Research Initiative
|
FDA
|
NCATS, OD/ DPCPSI/ OSC
|
2013
|
|
Extracting Adverse Reactions and Indexing the Content of Structured Product Labels (SPLs)
|
Resource Development
|
FDA
|
|
2016
|
|
Extraction of adverse drug events from MEDLINE indexing to support a multimodal model for pharmacovigilance.
|
Resource Development
|
FDA
|
|
2012
|
|
Eye Research Collaboration
|
Other
|
FDA
|
NEI
|
2014
|
|
FDA Acute Radiation Syndrome (ARS) Action Team
|
Committee, Advisory Group, or Work Group
|
FDA, OS
|
NIAID
|
2018
|
|
FDA Antimicrobial Drugs Advisory Committee (FDA AMDAC)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIAID
|
2021
|
|
FDA Collaboration - Psilocybin Research
|
Research Initiative
|
FDA
|
|
2020
|
|
FDA Microbiology Devices Panel of the Medical Devices Advisory Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIAID
|
2017
|
|
FDA-NIH Joint Leadership Council
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NHLBI, NIAID, NIDA, NIDDK, NINDS, OD/ IMOD, OD/ OER, OD/ OSP
|
2010
|
|
FDA/NIMH Points of Contact Working Group Meeting - Drugs
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2020
|
|
Federal Cannabis Partners
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, SAMHSA
|
NIDA, NCI
|
|
|
Federal Dietary Reference Intakes Steering Committee
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, OASH
|
NHLBI, NIDDK, OD/ DPCPSI
|
2005
|
|
Federal Experts Security Advisory Panel (FESAP)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID, OD/ OSP
|
2010
|
|
Federal HIV Web Council (HIV.gov) (FHWC)
|
Committee, Advisory Group, or Work Group
|
OASH, CDC, FDA, HRSA, IHS, SAMHSA, ACF
|
NIAID, NIDA, OD/ DPCPSI/ OAR
|
2006
|
|
Federal Hypertension Control Leadership Council
|
Meeting/ Workshop
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, ASPR, ONC
|
NHLBI, NINDS
|
2020
|
|
Federal Interagency Breastfeeding Working Group
|
Committee, Advisory Group, or Work Group
|
ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS
|
NCI, NHLBI, NICHD, NIDDK
|
2009
|
|
Federal Interagency Workgroup on Improving Diagnostic Safety and Quality in Health Care
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA, IHS, ONC, SAMHSA
|
NIBIB, NLM, CC, NCATS, NCI
|
2018
|
|
Federal Lead Action Plan Workgroup
|
Committee, Advisory Group, or Work Group
|
FDA, OS
|
|
|
|
Federal RePORTER
|
Resource Development
|
ACF, ACL, AHRQ, CDC, FDA
|
OD/ OER
|
2008
|
|
Federal Supply and Demand of Isotopes
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NIBIB
|
2012
|
|
Federal Tuberculosis (TB) Task Force
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS
|
NIAID, NICHD
|
1991
|
|
Federal Working Group on Bone Diseases
|
Committee, Advisory Group, or Work Group
|
CDC, CMS, FDA
|
CSR, NCATS, NCI, NIA, NIAID, NIAMS, NICHD, NIDCR, NIDDK, OD/ DPCPSI/ ORWH, NIAAA
|
1993
|
|
Filovirus Animal Non-Clinical Group (FANG)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID
|
2011
|
|
Filovirus Animal Non-Clinical Group (FANG) Workshop
|
Meeting/ Workshop
|
CDC, FDA, OS
|
NIAID
|
2018
|
|
FNIH Advanced Medicines Partnership® - Bespoke Gene Therapy Consortium (FNIH AMP BGTC)
|
Research Initiative
|
FDA
|
NCATS
|
2019
|
|
FNIH Biomarkers Consortium (FNIH)
|
Research Initiative
|
CMS, FDA
|
NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NINDS
|
2006
|
|
Foundation for the National Institutes of Health (FNIH) PACT (Partnership for Accelerating Cancer Therapies) (FNIH PACT)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI
|
2017
|
|
Full-text health-related documents at NLM (includes HSTAT) Bookshelf/Digital Repository
|
Resource Development
|
AHRQ, ATSDR, CDC, CMS, FDA, SAMHSA
|
|
1994
|
|
Funding Opportunity Announcement Module (FOAM)
|
Resource Development
|
ACF, ACL, AHRQ, CDC, CMS, FDA
|
CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/ AoU, OD/ DPCPSI, OD/ DPCPSI/ OAR, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ODS, OD/ DPCPSI/ ORIP, OD/ DPCPSI/ ORWH, OD/ DPCPSI/ OSC, OD/ DPCPS
|
2016
|
|
Gastrointestinal Steering Committee Neuroendocrine Tumor Clinical Trials Planning Meeting: Treatment in the Rea of Peptide Receptor Radionuclide Therapy - March 8-9,2021
|
Meeting/ Workshop
|
FDA
|
NCI
|
2021
|
|
Genome in a Bottle Consortium (GIAB)
|
Resource Development
|
CDC, FDA
|
NHGRI, NCI
|
2013
|
|
Global Substance Registration System (GSRS)
|
Research Initiative
|
FDA
|
NCATS
|
2013
|
|
Government-University-Industry Research Roundtable (GUIRR)
|
Committee, Advisory Group, or Work Group
|
FDA
|
OD/ IMOD
|
|
|
Gynecologic Cancer Steering Committee Clinical Trials Planning Meeting: Defining and Targeting Molecular Pathways to Direct Personalized Value-added Treatments for Patients with Epithelial Ovarian Cancer - February 25-26, 2021
|
Meeting/ Workshop
|
FDA
|
NCI
|
2021
|
|
Harmonization of various Common Data Models and Open Standards for Evidence Generation
|
Committee, Advisory Group, or Work Group
|
FDA, ONC
|
NCATS, NLM
|
2016
|
|
Harmonization of various Common Data Models and Open Standards for Evidence Generation (CDMH II)
|
Resource Development
|
FDA
|
NCATS, NCI, NLM
|
2016
|
|
HCS Research Collaboratory
|
Research Initiative
|
AHRQ, CDC, CMS, FDA, OS
|
OD/ DPCPSI/ ODP
|
2012
|
|
Healthy People 2030 - Chronic Kidney Disease Workgroup
|
Committee, Advisory Group, or Work Group
|
CDC, CMS, FDA, HRSA, OS
|
|
1998
|
|
Healthy People 2030 - Nutrition and Weight Status Workgroup
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OASH
|
NIDDK
|
2010
|
|
Healthy People 2030 - Social Determinants Working Group
|
Committee, Advisory Group, or Work Group
|
ACF, CDC, HRSA, OASH, SAMHSA, PSC, FDA
|
NIA, NCI, NIAAA, NIMHD
|
2016
|
|
Healthy People Initiative
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, CDC, FDA, HRSA, IHS, OS, SAMHSA
|
NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDCD, NIDDK, NIEHS, NIMH, NINDS
|
1979
|
|
Heart Failure Collaboratory
|
Meeting/ Workshop
|
CMS, FDA
|
|
2017
|
|
Heart Valve Collaboratory
|
Meeting/ Workshop
|
CMS, FDA
|
|
2020
|
|
Helping to End Addiction Long-Term Initiative (HEAL)
|
Research Initiative
|
AHRQ, CDC, CMS, FDA, SAMHSA
|
NCATS, NCCIH, NIA, NIAID, NIAAA, NIBIB, NIMH, NIDA, NICHD, OD, NINR, NHLBI, OD/ DPCPSI/ OBSSR, NIAMS, NIDDK
|
2018
|
|
HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis Interagency Implementation Group (VHIG)
|
Research Initiative
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NIAID, NIDA, NIDDK, NIMHD
|
2011
|
|
HHS Adolescent Health Working Group
|
Committee, Advisory Group, or Work Group
|
ACF, AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA
|
NIAAA, NICHD, NIDA, NIMH
|
2010
|
|
HHS Antiretroviral Treatment Guidelines Panel for Adults and Adolescents with HIV
|
Committee, Advisory Group, or Work Group
|
HRSA, CDC, FDA
|
NIAID
|
|
|
HHS Behavioral Health Coordinating Council (BHCC) Overdose Prevention Subcommittee
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA, OASH, ASPE
|
NIDA, OD/ OSP
|
2009
|
|
HHS Behavioral Health Coordinating Council, Subcommittee on Children and Youth
|
Committee, Advisory Group, or Work Group
|
HRSA, SAMHSA, FDA, OASH, CMS
|
NICHD, NIMH, NIDA
|
|
|
HHS Biannual Dual Use Research of Concern (DURC) Inventory
|
Resource Development
|
CDC, FDA, OS
|
CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/ DPCPSI, OD/ OSP
|
2012
|
|
HHS Biosafety and Biosecurity Coordinating Council (HHS BBCC)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
OD/ ORS, OD/ OSP
|
2015
|
|
HHS Border Health Intra-agency Working Group
|
Committee, Advisory Group, or Work Group
|
ACF, AHRQ, CDC, FDA, HRSA, OS
|
NIA, NIAID, NICHD, NIDDK, NIMH, NIMHD
|
|
|
HHS Coordination Operations and Response Element (previously Operation Warp Speed) (H-CORE/OWS)
|
Research Initiative
|
CDC, FDA, ASPR
|
NIAID
|
2020
|
|
HHS Data Council
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ASA, ASFR, ASPA, ASPE, ASPR, ATSDR, CDC, CMS, FDA, GDM, HRSA, IHS, ONC, OMHA
|
NLM, OD/ DPCPSI/ OBSSR, OD/ OER, OD/ DPCPSI/ ODSS
|
1996
|
|
HHS Dietary Guidance Review Committee
|
Committee, Advisory Group, or Work Group
|
ACF, CDC, FDA, HRSA, IHS, OASH
|
NIDDK
|
1990
|
|
HHS Disability Collaborative
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, ASPA, ASPE, ASFR, ASA, ASPR, ACF, CDC, CMS, OASH, OCR, ONC, OIG, OGA, HRSA, SAMHSA, FDA, IHS
|
NIA, NICHD
|
2020
|
|
HHS Ebola Medical Countermeasures Scientific Working Group
|
Committee, Advisory Group, or Work Group
|
ASPR, OGA, CDC, FDA
|
|
2018
|
|
HHS Global Health Collaborative
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA
|
|
|
|
HHS Health Disparities Council
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA
|
NIMHD
|
|
|
HHS HIV Bidirectional Meeting Planning Committee
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA, OS, SAMHSA
|
NIAID, NIMH
|
2018
|
|
HHS Kidney Care Work Group
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID
|
2018
|
|
HHS LGBT Policies Coordinating Committee (HHS LGBT CC)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA
|
NIMH, OD/ DPCPSI/ SGMRO
|
2011
|
|
HHS Maternal Health Working Group
|
Committee, Advisory Group, or Work Group
|
AHRQ, ACF, ASPE, CDC, CMS, FDA, HRSA, IHS, OASH, SAMHSA
|
NICHD, NHLBI, NIMHD
|
2020
|
|
HHS Minority Health Directors Committee
|
Meeting/ Workshop
|
AHRQ, CDC, CMS, HRSA, IHS, FDA, SAMHSA
|
|
2020
|
|
HHS Nutrition Planning Group for the White House Conference on Food, Hunger, and Health
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, NIH, OASH, SAMHSA, OS
|
NIDDK, NHLBI, NCI, OD/ DPCPSI/ ODP, OD/ DPCPSI/ ORWH
|
2021
|
|
HHS Panel on Antiretroviral Guidelines for Adults and Adolescents
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA
|
NIAID, NICHD, OD/ DPCPSI/ OAR
|
|
|
HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA
|
NIAID, NICHD, OD/ DPCPSI/ OAR
|
|
|
HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA
|
NIAID, NICHD, OD/ DPCPSI/ OAR
|
|
|
HHS Potential Pandemic Pathogens Care and Oversight Review Group
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID, OD/ OSP
|
2018
|
|
HHS Social Determinants of Health Workgroup
|
Committee, Advisory Group, or Work Group
|
ACL, ACF, AHRQ, CDC, HRSA, IHS, OASH, FDA, CMS, SAMHSA
|
NIA, NICHD
|
2019
|
|
HHS Tick-Borne Diseases Working Group
|
Committee, Advisory Group, or Work Group
|
CDC, CMS, FDA, OS
|
NIAID
|
2017
|
|
HHS Tobacco Control Steering Committee
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA, SAMHSA, OS
|
NCI, NIDA
|
2021
|
|
HHS Viral Hepatitis Interagency Working Group
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA, OASH, ONC
|
NIDA, OD/ DPCPSI/ OAR, NIAID
|
2009
|
|
HHS-NASA Scientific Potential/Actual Collaborative Efforts (SPACE) group
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ASPR, OASH
|
FIC, NCATS, NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NIBIB, NICHD, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, NINDS, OD/ IMOD
|
2018
|
|
HHS-Wide Stigma Workgroup
|
Research Initiative
|
CDC, FDA, HRSA, IHS, SAMHSA
|
|
2019
|
|
Human skin sensitization data set
|
Research Initiative
|
FDA
|
|
2020
|
|
IAA with FDA - Using big data to compare SARS-CoV-2 infection and therapeutic efficacy between human lung on a chip and animal model testing
|
Resource Development
|
FDA
|
NIAID
|
2020
|
|
ICCVAM Ecotoxicology Workgroup (EcoWG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2018
|
|
ICCVAM In Vitro to In Vivo Extrapolation Workgroup (IVIVE-WG)
|
Committee, Advisory Group, or Work Group
|
ATSDR, FDA
|
NLM
|
2017
|
|
ICCVAM Metrics Workgroup (MWG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
OD
|
2019
|
|
ICCVAM Nanomaterials Workgroup (NanoWG)
|
Committee, Advisory Group, or Work Group
|
FDA, CDC
|
|
2018
|
|
ICCVAM Public Forum
|
Meeting/ Workshop
|
FDA
|
NCATS
|
2014
|
|
ICCVAM Read Across Workgroup (RAWG)
|
Committee, Advisory Group, or Work Group
|
ATSDR, FDA
|
NLM
|
2017
|
|
Identification and Validation of ctDNA Quality Control Materials
|
Resource Development
|
FDA
|
NCI
|
2019
|
|
Image-guided Interventional Therapeutics
|
Research Initiative
|
FDA
|
CC, NCI
|
2004
|
|
Immunology Interest Group
|
Meeting/ Workshop
|
FDA
|
NIDDK, NCI, NHLBI, NIAID, NINDS, NIEHS, CC, NIAMS, NEI, NIDCR, NICHD, NIAAA, NIMH, NHGRI, NCCIH, NIA, NIDA, NIDCD, NIGMS, NIMHD, OD/ OIR
|
1990
|
|
Improving Genomics/Omics Technical Standards and Molecular Tools for Prebiotic Probiotic Research and Development Working Group
|
Research Initiative
|
CDC, FDA, OS
|
NCCIH, NCI, NHGRI, NIDA, NLM
|
2016
|
|
Improving Steps in the Development and Assessment of Live Microbiome-Based Products: Fecal Microbiota for Transplantation (FMT) and Live Biotherapeutic Products (LBPs)
|
Resource Development
|
FDA
|
NIAID
|
2019
|
|
In Vitro Assessment of Dermal Hypersensitivity: Using Alternative Methods to Predict Skin Sensitization
|
Research Initiative
|
FDA
|
NIEHS
|
2018
|
|
Inclusion Across the Lifespan
|
Meeting/ Workshop
|
FDA
|
NCI, NHLBI, NIA, NICHD, NIDCR, NIMHD, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ORWH, OD/ OER
|
2016
|
|
Influenza Diagnostics Risk Management Meeting (FRMM) Strategy Working Group
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ASPR
|
NIAID
|
2018
|
|
Influenza Risk Management Meeting
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID
|
2007
|
|
Inter-Agency Working Group on the National Healthcare Quality and Disparities Report
|
Committee, Advisory Group, or Work Group
|
ACF, AHRQ, CDC, CMS, HRSA, IHS, OS, ASPE, FDA
|
NCI, NHLBI, NIMHD, OD/ DPCPSI
|
2015
|
|
Interagency Agreement NTP/NIEHS and NCTR/FDA (IAA)
|
Other
|
FDA
|
|
1993
|
|
Interagency Artificial Pancreas Working Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIBIB, NICHD
|
2007
|
|
Interagency Autism Coordinating Committee (IACC)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NICHD, NIEHS, NINDS, NIDCD
|
2000
|
|
InterAgency Board (IAB)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ATSDR
|
NIEHS
|
2010
|
|
Interagency Collaborative Animal Research Education (ICARE) Training Project
|
Training Initiative
|
CDC, FDA, ASPR
|
OD/ OER
|
2016
|
|
Interagency Collaborative to Advance Research in Epilepsy (ICARE)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA, OS
|
FIC, NCATS, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDA, NIMH, NINDS
|
2003
|
|
Interagency Committee on Disability Research (ICDR)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA
|
NICHD, NIDCD, NIMH, NINDS
|
1988
|
|
Interagency Committee on Human Nutrition Research (ICHNR)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA
|
NIDDK, NCI, OD/ DPCPSI
|
2013
|
|
Interagency Committee on Smoking and Health
|
Committee, Advisory Group, or Work Group
|
CDC, CMS, FDA, HRSA, SAMHSA
|
NCI, NIDA
|
1985
|
|
Interagency Coordinating Committee for Newborn Screening
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA
|
NICHD
|
2008
|
|
Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt - Jakob disease
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD, NINDS
|
1985
|
|
Interagency Coordinating Committee on the Validation of Alternative Toxicological Methods (ICCVAM)
|
Committee, Advisory Group, or Work Group
|
ATSDR, FDA, CDC
|
NCI, OD, NLM
|
2003
|
|
Interagency Group for Development of Lung Infection Models for P. aeruginosa and A.baumannii
|
Committee, Advisory Group, or Work Group
|
BARDA, CDC, FDA
|
NIAID
|
2018
|
|
Interagency Group on Alzheimer& Disease and Related Dementias for implementation of the National Alzheimer& Project Act
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, AoA, ASPE, ACF, IHS, OASH, SAMHSA
|
NIA
|
2011
|
|
Interagency Modeling and Analysis Group (IMAG)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA
|
CSR, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM, OD/ DPCPSI, OD/ DPCPSI/ OBSSR
|
2003
|
|
Interagency Morphine Milligram Equivalent (MME) Workgroup
|
Committee, Advisory Group, or Work Group
|
FDA, CDC
|
NIDA
|
|
|
Interagency Oncology Task Force Fellowship: Track 4
|
Training Initiative
|
FDA
|
NCI
|
2005
|
|
Interagency Pain Research Coordinating Committee (IPRCC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, SAMHSA
|
NCCIH, NIDA, NIDCR, NINDS, NINR, NIA
|
2011
|
|
Interagency Task Force on Trauma-Informed Care
|
Committee, Advisory Group, or Work Group
|
ACF, AHRQ, CDC, FDA, HRSA, IHS, OS, SAMHSA
|
NICHD
|
2018
|
|
Interagency Workgroup on Coordinating Opportunities for Evaluating Dolutegravir and Neural Tube Defects Association
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD, NIAID
|
2018
|
|
Interagency Workgroup on Technology to Facilitate Aging in Place
|
Research Initiative
|
ACL, CMS, FDA
|
NCI, NHLBI, NIA, NIBIB, NINDS, NINR
|
2014
|
|
Interagency Working Group in the Glycosciences
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NICHD, NIDCR, NIDDK, NIGMS
|
2008
|
|
Interagency working group on Biological Data Sharing
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NIGMS
|
2018
|
|
Interagency Working Group on Harmful Algal Bloom and Hypoxia Research and Control Act (IWG-HABHRCA)
|
Committee, Advisory Group, or Work Group
|
FDA, CDC
|
|
2014
|
|
Interdepartmental Health Equity Collaborative (formerly FIHET)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, NINR, OD/ DPCPSI/ ODP
|
2006
|
|
Interdepartmental Health Equity Collaborative (IHEC)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA
|
NCI, NHLBI, NIA, NIAID, NICHD, NIMH, NIMHD
|
2006
|
|
International Neonatal Consortium
|
Meeting/ Workshop
|
FDA
|
NICHD
|
2015
|
|
International Rare Diseases Research Consortium (IRDiRC) Funders Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCATS, NCI, NEI, NHGRI, NIAMS, NICHD, NINDS
|
2011
|
|
Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NCI, NIAID, OD/ ORS, OD/ OSP
|
2005
|
|
JDRF/NIH Beta Cell Replacement Workshop
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIDDK, NIAID
|
2021
|
|
Joint Agency Microbiome Working Group (JAM)
|
Committee, Advisory Group, or Work Group
|
FDA
|
OD/ DPCPSI/ ONR
|
2017
|
|
Joint Agency Nutrition Working Group (JAN)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NICHD, NIDDK, OD/ DPCPSI
|
2016
|
|
Joint External Evaluation Working Group (JEEWG)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NCI, NIEHS, NINDS, OD/ ORS, OD/ OSP
|
|
|
Joint Fellowship Program
|
Training Initiative
|
FDA
|
|
2005
|
|
Kidney Innovation Accelerator (KidneyX)
|
Research Initiative
|
FDA
|
NCATS
|
2018
|
|
Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NCCIH, NCI, NHLBI, NIA, NICHD, NINDS, OD/ DPCPSI/ OBSSR
|
1987
|
|
LGBT Healthy People 2030 Working Group (LGBT HP 2030)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA
|
NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NINDS, OD/ DPCPSI/ ODP, OD/ DPCPSI/ SGMRO
|
2019
|
|
Lower Limb Prosthetics Research Standards Working Group
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, CMS, FDA
|
NIDDK, NICHD, OD
|
|
|
Lupus Federal Working Group
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA, OS
|
NCCIH, NEI, NHLBI, NIAID, NIAMS, NICHD, NIDCR, NIDDK, NIEHS, NIMHD, NINDS, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ORWH
|
2003
|
|
Lyme and Tick-borne Diseases Work Group
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS, CMS
|
NIAID
|
2011
|
|
Machine learning methods for literature data extraction
|
Research Initiative
|
FDA
|
|
2018
|
|
Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs
|
Resource Development
|
ASPE, FDA
|
|
2021
|
|
Materials Genome Initiative (MGI)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIBIB
|
2018
|
|
Maternal Health Working Group
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
NHLBI, NICHD, NIMHD, OD/ DPCPSI/ ORWH
|
2019
|
|
Memorandum of Understanding (MOU) between the FDA Center for Devices and Radiological Health and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
2015
|
|
Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
2002
|
|
Microphysiological Systems for Drug Efficacy and Toxicity Testing (Tissue Chip for Drug Screening)
|
Research Initiative
|
FDA, ASPR
|
NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/ DPCPSI/ ORWH, OD/ DPCPSI/ OSC
|
2012
|
|
Monthly Zika Vaccine Development Meeting
|
Resource Development
|
BARDA, FDA
|
NIAID
|
2018
|
|
Mortality Disparities in American Communities (MDAC) Study
|
Research Initiative
|
CDC, FDA
|
NCI, NIA
|
1985
|
|
Muscular Dystrophy Coordinating Committee (MDCC)
|
Committee, Advisory Group, or Work Group
|
ACL, CDC, FDA, HRSA
|
NHLBI, NIAMS, NICHD, NINDS
|
2002
|
|
MyHealthfinder Steering Committee
|
Committee, Advisory Group, or Work Group
|
ODPHP, OASH, AHRQ, CDC, HRSA, FDA, CMS, SAMHSA
|
NCI, NIA
|
2021
|
|
Nanotechnology Characterization Laboratory
|
Research Initiative
|
FDA
|
|
2004
|
|
NAPA Federal Subgroup
|
Committee, Advisory Group, or Work Group
|
AHRQ, ASPE, ACL, CDC, CMS, FDA, HRSA, IHS
|
NIA, NINDS
|
2014
|
|
NASEM Forum on Drug Discovery, Development, and Translation
|
Committee, Advisory Group, or Work Group
|
FDA, ASPR
|
NINDS, NIAID, NCI, NIMH, OD/ OSP
|
|
|
National Academy of Medicine Committee on Emerging Science, Technology, and Innovation in health and medicine
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2020
|
|
National Action Plan for Combating Antoibiotic-Resistant Bacteria (CARB) 2020-2025
|
Committee, Advisory Group, or Work Group
|
AHRQ, BARDA, CDC, CMS, FDA, HRSA, OS
|
NIAID
|
2019
|
|
National Advisory Committee on Children and Disasters (NAACD)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA, ASPR
|
NICHD, NIEHS
|
|
|
National Center for Advancing Translational Sciences (NCATS) Toolkit for Patient-focused Therapy Development
|
Resource Development
|
FDA
|
NCATS
|
2017
|
|
National Clinical Care Commission (NCCC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
|
2018
|
|
National Clinical Trials Network (NCTN) Scientific Steering Committees (SSCs)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI
|
2008
|
|
National Coalition for Oversight of Assisted Reproductive Technologies (NCOART)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
1997
|
|
National COVID Cohort Collaborative (N3C)
|
Research Initiative
|
FDA, ASPR, CMS
|
NIGMS
|
2021
|
|
National Database for Antibiotic Resistant Organisms (NDARO)
|
Resource Development
|
CDC, FDA
|
CC, FIC, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIDA
|
2016
|
|
National Emerging Contaminant Research Initiative
|
Research Initiative
|
CDC, ATSDR, FDA
|
|
|
|
National HIV/AIDS Strategy Steering Committee (NHAS)
|
Committee, Advisory Group, or Work Group
|
OASH, CDC, HRSA, IHS, SAMHSA, CMS, FDA, ACL, AHRQ
|
NIAID, NIDDK, OD/ DPCPSI/ OAR
|
2021
|
|
National Hospital Care Survey (NHCS) Patient-Centered Outcomes Research Trust Fund (PCORTF) Project
|
Other
|
CDC, SAMHSA, ASPE, FDA
|
NIDA, NIMH
|
|
|
National Institutes of Health (NIH) Flow Cytometry Interest Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
CC, NEI, NHLBI, NIAID, NIAMS, NIDCR
|
2005
|
|
National Institutes of Health (NIH) Health Communication Workshop
|
Meeting/ Workshop
|
FDA
|
NIDA, NCI, OD/ DPCPSI/ ODP
|
2021
|
|
National Interagency Confederation for Biological Research
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2002
|
|
National Nanotechnology Initiative (NNI) Nanotechnology Signature Initiative on Nanotechnology Knowledge Infrastructure: Enabling National Leadership in Sustainable Design
|
Committee, Advisory Group, or Work Group
|
FDA, CDC
|
NCI, NIBIB
|
2012
|
|
National PAD Action Plan
|
Committee, Advisory Group, or Work Group
|
CDC, CMS, FDA
|
NIA, NIDDK
|
2018
|
|
National Pain Strategy. Provider Eduction Committee (NPS)
|
Committee, Advisory Group, or Work Group
|
CDC, HRSA, FDA, OASH
|
NINDS
|
2016
|
|
National Science Advisory Board for Biosecurity
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID, OD/ OSP
|
2004
|
|
National Science and Technology Council, Office of Science and Technology Policy, Subcommittee on Open Science (NSTC OSTP SOS)
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, ASPR, CDC, FDA
|
OD/ OSP, OD/ OER
|
|
|
National Sexually Transmitted Infections (STI) Strategic Plan
|
Committee, Advisory Group, or Work Group
|
OASH, ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NIAID
|
2020
|
|
National Toxicology Board of Scientific Counselors (NTP BSC)
|
Meeting/ Workshop
|
CDC, FDA
|
|
1978
|
|
National Toxicology Program Executive Committee (NTP EC)
|
Meeting/ Workshop
|
ATSDR, CDC, FDA, OASH
|
|
1978
|
|
National Toxicology Program Steering Committee (NTP SC)
|
Meeting/ Workshop
|
CDC, FDA
|
|
2003
|
|
NCATS N3C Collaboration
|
Resource Development
|
FDA
|
NCATS
|
2020
|
|
NCI Cancer Data Standards Repository and Registry (caDSR)
|
Committee, Advisory Group, or Work Group
|
FDA, ASPE
|
CIT, NEI, NHLBI, NIAMS, NIBIB, NICHD, NIMH, NINDS, NLM, NCATS, NCI, NIDA, NIDCD
|
2000
|
|
NCI Cervical Cancer "Last Mile" Initiative (LMI)
|
Research Initiative
|
FDA, CDC
|
NCI
|
2021
|
|
NCI Clinical Trials and Translational Research Advisory Committee (CTAC)
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NCI
|
2007
|
|
NCI Convenes Workshop on Reproducibility of Fecal Microbiota Transplants in Cancer Therapeutics
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI
|
2019
|
|
NCI Enterprise Vocabulary Services (EVS) controlled terminology and standards development in collaboration with FDA and international regulatory agencies including NCI/FDA Memorandum of Understanding for Drug Related Information
|
Resource Development
|
FDA
|
|
2012
|
|
NCI/CCR-FDA Clinical Investigator Program
|
Research Initiative
|
FDA
|
|
2015
|
|
NCI/FDA Memorandum of Understanding for Proteomics
|
Research Initiative
|
FDA
|
NCI
|
2007
|
|
NCI/FDA/HRSA/CMS Task Force on Cancer Diagnostic Devices (CD2) for Near-Patient Use
|
Committee, Advisory Group, or Work Group
|
CMS, FDA, HRSA
|
|
2019
|
|
NEI-FDA-ONC Joint Workshop on Promoting Adoption of Ocular Imaging Standards
|
Meeting/ Workshop
|
FDA, ONC
|
NEI
|
2021
|
|
Newborn Screening Coding and Terminology Guide
|
Resource Development
|
CDC, FDA, HRSA, IOS
|
NHGRI, NHLBI, NICHD
|
2007
|
|
Newborn Screening Federal Partners Committee
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA
|
NICHD, NHGRI, NLM
|
2009
|
|
Next Generation Microfluidics Workshop
|
Meeting/ Workshop
|
FDA
|
|
2021
|
|
NIAID/FDA/BARDA Meeting on Cutaneous Radiation Injuries
|
Meeting/ Workshop
|
BARDA, FDA
|
NIGMS
|
2018
|
|
NIAID/FDA/BARDA Meeting on Gastrointestinal Acute Radiation Syndrome (GI-ARS)
|
Meeting/ Workshop
|
FDA, ASPR
|
|
2021
|
|
NIAID/FDA/BARDA Meeting on Radiation-Induced Lung Injuries
|
Meeting/ Workshop
|
FDA, ASPR
|
NIAID
|
2018
|
|
NIAID/NASA Medical Countermeasures Working Group
|
Committee, Advisory Group, or Work Group
|
BARDA, FDA
|
NCI, NHLBI
|
2017
|
|
Nicotine Research Cigarettes (SPECTRUM)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIDA
|
2013
|
|
NIDA-FDA Interagency Clinical Outcomes Assessment Working Group (ICOAWG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIDA, NCI, OD/ DPCPSI/ OBSSR
|
|
|
NIEHS SBIR PHASE IIB Awards for Validation and Commericialization of Approaches to Reduce Animal Use in Toxicology Testing (U44)
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2016
|
|
NIH Autoimmune Diseases Coordinating Committee (ADCC)
|
Committee, Advisory Group, or Work Group
|
FDA, HRSA
|
NIAID, OD, NCI, NCATS, NCCIH, NEI, NHLBI, NHGRI, NIAMS, NIBIB
|
2003
|
|
NIH Common Data Elements Task Force (CDETF)
|
Committee, Advisory Group, or Work Group
|
AHRQ, FDA, CMS, ASPE, CDC
|
CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NCRR, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NINDS, NINR, NLM, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ODSS, OD/ OER, OD/ AoU, OD/ DPCPSI/ ODP, OD/ DPCPSI/ ORWH, OD/ DPCPSI/ SGMRO, OD/ ECHO, NIGMS, NIMH, NIMHD
|
2012
|
|
NIH COVID-19 Treatment Guidelines Panel
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2020
|
|
NIH Guide for Grants and Contracts
|
Resource Development
|
AHRQ, CDC, FDA
|
CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/ DPCPSI, OD/ OER
|
2007
|
|
NIH-FDA Interagency Clinical Outcome Assessments Working Group (ICOAWG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, CC, NHLBI, NIA, NIAMS, NICHD, NIDA, NIDDK, NIMH, NINDS, OD/ DPCPSI
|
2010
|
|
NIH-FDA Medical Device Research Interest Group and Medical Imaging and Data Resource Center (MDRIG)
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NCATS, NCI, NEI, NHLBI, NIA, NIAID, NIBIB, NICHD, NIDDK, NINR, OD/ DPCPSI/ ORIP, FIC, NIAMS, NIDA
|
2016
|
|
NIH/BARDA Antimicrobial Resistance (AMR) Diagnostic Challenge Working Group
|
Research Initiative
|
ASPR, FDA, CDC
|
NIAID
|
2015
|
|
NIH/BMGF Collaboration - Point of Care Testing Working Group
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NCI, NIAID, NIBIB, NICHD
|
2016
|
|
NINDS Common Data Elements Program
|
Resource Development
|
CDC, FDA
|
CIT, NINDS, NICHD, NEI, NHGRI, NCATS, NIA, NIMH, NIEHS, NIGMS, NIBIB, NIDDK, NIDCR, NINR, NHLBI
|
2006
|
|
Non-animal approaches to assess cardiotoxicity hazard
|
Research Initiative
|
FDA
|
|
2018
|
|
NSTC Subcommitee on Open Science (NSTC SOS)
|
Committee, Advisory Group, or Work Group
|
AHRQ, ASPR, CDC, FDA
|
OD/ DPCPSI/ ODSS
|
2016
|
|
NSTC Subcommittee on Biological Sciences
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
OD/ OSP
|
|
|
Nutrition Sub-Interagency Policy Council
|
Committee, Advisory Group, or Work Group
|
FDA, CMS, IOS, OASH
|
|
2021
|
|
Office of National Drug Control Policy (ONDCP) Data Interagency Working Group (DIWG)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ASA, ASPE, CDC, CMS, FDA, IHS, NIH, ONC, SAMHSA
|
NIDA, NIAAA
|
2021
|
|
Office of the National Coordinator for Health Information Technology (ONC)
|
Resource Development
|
FDA, ONC
|
NLM
|
2020
|
|
Older Adults Individual Collaborative on Nutrition (OICN)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, NIH, OASH, OS
|
OD/ DPCPSI/ ODP, OD/ DPCPSI/ ODS, OD/ DPCPSI/ ONR
|
|
|
Open Science Infrastructure Working Group of the Subcommittee on Open Science of the National Science and Technology Council (OSI)
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, ASPR, CDC, FDA
|
OD/ DPCPSI/ ODSS, OD/ OSP, OD/ OER
|
2021
|
|
ORWH E-learning courses
|
Training Initiative
|
FDA
|
NIGMS
|
2020
|
|
P63, P13K and RAS oncogenes in tumorigenesis, immune deregulation and therapy of squamous cell carcinoma
|
Research Initiative
|
FDA
|
NIDCD
|
2014
|
|
Pathogen Detection Project and Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS)
|
Resource Development
|
CDC, FDA
|
|
2015
|
|
PCC Technical Working Group on PFAS
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ATSDR
|
|
|
|
Pediatric COVID-19/MIS-C Interagency Team
|
Committee, Advisory Group, or Work Group
|
FDA, CDC, ASPR
|
NICHD, NHLBI, NIAID
|
|
|
Pediatric COVID-19/Multisystem Inflammatory Syndrome in Children (MIS-C) interagency team
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA
|
NHLBI, NICHD
|
2020
|
|
Pilot Biosurveillance Working Group - National Biodefense Strategy
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ASPR
|
NIAID
|
2021
|
|
Policies and Regulatory Pathways to FDA Licensure
|
Meeting/ Workshop
|
FDA
|
NIAID
|
2018
|
|
Population Assessment of Tobacco and Health (PATH) Study
|
Health Survey
|
FDA
|
NIDA
|
2011
|
|
Post Market Safety Study of Opoids
|
Research Initiative
|
FDA
|
NIDA
|
2014
|
|
Postdoctoral Fellowship in Genomic Science and Health Equity
|
Training Initiative
|
FDA
|
|
2021
|
|
Preclinical Assessment of Phage Therapy for Pathogen Decolonization
|
Research Initiative
|
FDA
|
NIAID
|
2015
|
|
Predictive Biodosimetry Guidance Planning Working Group
|
Committee, Advisory Group, or Work Group
|
ASPR, FDA
|
NIAID
|
2020
|
|
Pregnancy and Birth to 24 Months (P/B-24) Project
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA, OS
|
NCI, NHLBI, NICHD, NIDDK
|
2012
|
|
President's Task Force on Environmental Health Risks and Safety Risks to Children (PTFCEH)
|
Committee, Advisory Group, or Work Group
|
ACF, ASPR, CDC, ATSDR, FDA, OASH, SAMHSA
|
NICHD, NHLBI, NIMH, NIMHD
|
|
|
President's Task Force on Environmental Health Risks and Safety Risks to Children: Lead Exposures Subcommittee
|
Committee, Advisory Group, or Work Group
|
ACF, CDC, FDA, HRSA, OS
|
NHLBI, NICHD, NIEHS, OD/ DPCPSI/ ODP
|
|
|
Prevention Research Coordinating Committee (PRCC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, OS, FDA, OASH
|
CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/ DPCPSI/ OAR, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ORWH, OD/ DPCPSI/ ODS, OD/ OLPA
|
1997
|
|
Probiotic and Prebiotic Working Group [PPWG] (PPWG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCCIH, NCI, NIAMS, NIDA, NIDCR, OD/ DPCPSI/ ODS, CC, CIT, CSR, FIC, NCATS, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OEDI
|
2006
|
|
Promoting Semantic Interoperability of Laboratory Data Test Results
|
Resource Development
|
CDC, FDA
|
|
2015
|
|
Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE)
|
Committee, Advisory Group, or Work Group
|
ACF, CDC, FDA, OS, SAMHSA
|
NIAID, NIAMS, NICHD, NINDS, NLM
|
2007
|
|
Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Preparedness Against Chemical Threats (PACT) Working Group (PHEMCE PACT Working Group)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID, NINDS
|
2007
|
|
Public Health Service Technology Transfer Policy Board (TTPB)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
|
1994
|
|
Quantitative Data Mining for Drug-Adverse Event Safety Signal Detection Using MEDLINE
|
Research Initiative
|
FDA
|
|
2012
|
|
Quantum Barcoding for analysis of Ebola infection
|
Resource Development
|
FDA
|
NIAID
|
2019
|
|
Radiation and Chemical Defense Working Group
|
Committee, Advisory Group, or Work Group
|
ASPR, FDA
|
NIEHS, NIAMS
|
2020
|
|
Radiation Biodosimetry Working Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIAID
|
2012
|
|
Radiobiology Bioterrorism Research and Training Group (RABRAT)
|
Meeting/ Workshop
|
FDA, OS, ASPR
|
NCI, NIAID
|
2003
|
|
Rapid Acceleration of Diagnostics Tech Program (RADx Tech)
|
Research Initiative
|
CMS, FDA, CDC, ASPR
|
NIBIB
|
2020
|
|
Rare Disease Day at NIH
|
Meeting/ Workshop
|
FDA
|
NCATS, NHLBI, NCI, NHGRI, CC, NIAAA
|
2011
|
|
Rare Diseases Registry Program (RaDaR)
|
Resource Development
|
FDA
|
|
|
|
Reciprocal Educational and Training Partnerships between FDA/CDER and the NIH Clinical Center
|
Training Initiative
|
FDA
|
CC, NCI, NIAID, NIDCR, NIDDK, NIMH, NINDS
|
2007
|
|
Recognize, Assist, Include, Support and Engage (RAISE) Family Caregiving Advisory Council
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NIA
|
2018
|
|
Regenerative Medicine Innovation Project Senior Oversight Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCATS, NEI, NHLBI, NIA, NIAID, NIAMS, NIDCD, NIDCR, NIDDK, NINDS
|
2018
|
|
Regenerative Medicine Project
|
Research Initiative
|
FDA
|
NIA
|
2017
|
|
Registry-based studies of hematologic malignancy incidence and survivorship
|
Research Initiative
|
FDA
|
|
2019
|
|
Role of IFNL4 in immune response to infection
|
Research Initiative
|
FDA
|
|
2018
|
|
RxNorm
|
Resource Development
|
FDA
|
|
2005
|
|
Sabbatical in Clinical Research Management Program
|
Training Initiative
|
FDA, OS
|
CC, FIC, NCATS, NEI, NHLBI, NIAID, NIDCR, NIDDK
|
2009
|
|
SARS-CoV-2 Interagency Group on Resistance to Medical Countermeasures (MCMs)
|
Committee, Advisory Group, or Work Group
|
ASPR, CDC, FDA
|
|
2021
|
|
SARS-CoV-2 Assay Development, Training, and Standardization
|
Resource Development
|
FDA
|
NIAID
|
2020
|
|
SARS-CoV-2 Assessment of Viral Evolution Program (SAVE)
|
Committee, Advisory Group, or Work Group
|
FDA, CDC, ASPR
|
NIAID
|
2021
|
|
SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES)
|
Other
|
CDC, FDA
|
NIAID
|
2020
|
|
Sequencing Quality Control Phase 2 (SEQC2)
|
Resource Development
|
FDA
|
NLM, CIT, NCI, NHLBI, NIEHS
|
2017
|
|
SHIELD Standardization of Lab Data to Enhance Outcomes Research and Value Based Care (SHIELD)
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
|
|
Smokefree.gov
|
Resource Development
|
CDC, FDA, IHS
|
NIMHD
|
2003
|
|
Somatic Cell Genome Editing
|
Research Initiative
|
FDA
|
NCATS, NCI, NHGRI, NHLBI, NIAID, NIAMS, NIDDK, NIMH, NINDS, OD/ DPCPSI/ ORIP, OD/ DPCPSI/ OSC
|
2017
|
|
Standardization of Lab Data to Enhance Outcomes Research and Value Based Care (SHIELD)
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
|
|
Steering Committee Meeting for PAR 18-947/PAR 22-049: "Integrating Biospecimen Science Approaches into Clinical Assay Development"
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI
|
2020
|
|
Steering Committee of the Scientific Interest Group in Glycobiology
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NHGRI, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIGMS
|
2008
|
|
Stimulating Peripheral Activity to Relieve Conditions (SPARC)
|
Research Initiative
|
FDA
|
NCATS, NCCIH, NCI, NEI, NHLBI, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NIMH, NINDS, OD/ DPCPSI/ OSC
|
2016
|
|
STS/ACC TVT Registry
|
Meeting/ Workshop
|
CMS, FDA
|
|
|
|
Subcommittee on Open Science (Formerly Interagency Working Group on Open Science)
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, CDC, FDA, OS
|
NLM, OD/ OER, OD/ OSP
|
2013
|
|
Support for Implementation of Agency Public Access Policies
|
Resource Development
|
AHRQ, CDC, FDA, IOS
|
OD/ OSP
|
2013
|
|
System of Hospitals for Innovation in Pediatrics - Medical Devices (SHIP-MD)
|
Meeting/ Workshop
|
FDA
|
NICHD
|
|
|
Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT)
|
Resource Development
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, SAMHSA
|
|
2003
|
|
Task Force for Combating Antibiotic-Resistant Bacteria (CARB)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, ASPR
|
NIAID
|
2014
|
|
Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA, OS
|
NCATS, NCCIH, NHLBI, NIAID, NICHD, NIDDK, NIMH, OD/ DPCPSI/ ORWH
|
2017
|
|
Technology Transfer Policy Board (TTPB)
|
Other
|
FDA, CDC, Office of General Counsel - OGC
|
OD/ OSP, OD/ OIR, OD/ OER
|
1995
|
|
The Assay Guidance Manual (AGM)
|
Resource Development
|
FDA
|
NCATS
|
2020
|
|
The Effect of Various Drugs on the Retina
|
Research Initiative
|
FDA
|
NEI
|
2014
|
|
The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM)
|
Research Initiative
|
CDC, FDA
|
NHGRI, NHLBI
|
2010
|
|
The Impact of Tobacco Use on Oral Health and the Oral Microbiome
|
Research Initiative
|
CDC, FDA
|
|
2012
|
|
The MDEpiNet TMJ RoundTable
|
Meeting/ Workshop
|
AHRQ, FDA
|
|
2016
|
|
The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ATSDR
|
OD/ OSP
|
2001
|
|
The Nutiriton Research Coordinating Committee (NRCC)
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, ASPE, CDC, FDA, HRSA, OASH
|
|
1975
|
|
The President's Task Force on Environmental Health risks and Safety risks to children; Asthma Disparities working group
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, IHS
|
NIAID, NICHD, NIMHD, NINR
|
2012
|
|
The Serological Sciences Network (SeroNet)
|
Committee, Advisory Group, or Work Group
|
FDA, CDC, ASPR
|
NIAID, NCI, CC
|
2010
|
|
Tissue Chip Testing Centers (TCTC)
|
Research Initiative
|
FDA
|
NCATS
|
2016
|
|
Tobacco and Nicotine Research Interest Group (TANRIG)
|
Committee, Advisory Group, or Work Group
|
CDC, SAMHSA, FDA, CMS
|
FIC, NCI, NEI, NHGRI, CSR, NCCIH, NIAMS, NIMH
|
2003
|
|
Tobacco Centers of Regulatory Science (TCORS)
|
Research Initiative
|
FDA
|
|
2013
|
|
Tobacco Product Disease Risks
|
Research Initiative
|
FDA
|
|
2016
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIEHS, OD/ OER
|
2012
|
|
Tobacco Use Supplement to Current Population Survey (TUS-CPS)
|
Health Survey
|
CDC, FDA
|
NCI, NIMHD
|
1992
|
|
Toxicology in the 21st Century (Tox 21)
|
Resource Development
|
FDA
|
NCATS, NIEHS
|
2008
|
|
Toxicology in the 21st Century Federal Consortium (NTP NCATS Interagency Agreement, ES-7020-01, Year 11) (Tox21)
|
Research Initiative
|
FDA
|
NIEHS, NCATS
|
2007
|
|
Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2015
|
|
Toxins Assessment Working Group
|
Committee, Advisory Group, or Work Group
|
ASPR, CDC, FDA
|
NIAID
|
2019
|
|
Tracking Resistance and Coronavirus Evolution (TRACE)
|
Resource Development
|
ASPR, CDC, FDA
|
NIAID
|
2021
|
|
Trans-Agency (Medical) Imaging Phantom (TAIP) Workgroup
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIBIB
|
2021
|
|
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, ASPR
|
NIAID
|
2009
|
|
Trans-HHS program for Multi-System Inflammatory Syndrome in Children (MIS-C) and pediatric SARS-CoV-2 (CARING)
|
Research Initiative
|
CDC, FDA, OASH
|
|
2020
|
|
Trans-NIH Working Group for Objective Measures in Cancer
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NIBIB, NIDDK
|
2017
|
|
Translational Science Interagency Fellowship (TSIF)
|
Training Initiative
|
FDA
|
NCATS
|
2020
|
|
Trial Transparency via Registration and Results Reporting at NIH ClinicalTrials.gov
|
Resource Development
|
FDA
|
CC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/ DPCPSI/ OBSSR, OD/ OER, OD/ OLPA, OD/ OSP
|
2000
|
|
Tularemia Animal Model Qualification Working Group
|
Committee, Advisory Group, or Work Group
|
BARDA, FDA
|
NIAID
|
2013
|
|
Tumor Mutational Burden (TMB) Harmonization Project
|
Resource Development
|
FDA
|
NCI
|
2018
|
|
U.S. and Canada Human Milk Composition Initiative (HMCI)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD, OD/ DPCPSI/ ODS, NIDDK, NCI
|
|
|
U.S. FDA Medical Imaging Drugs Advisory Committee
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2015
|
|
Understanding and Identifying the Needs for Medical Devices
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCATS
|
2014
|
|
Unified Medical Language System Metathesaurus (UMLS)
|
Resource Development
|
AHRQ, CDC, CMS, FDA
|
|
1990
|
|
United States Government Global Nutrition Coordination Plan
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
2016
|
|
Urine biomarkers and risk of lung cancer in the Sisters Study
|
Research Initiative
|
CDC, FDA
|
|
2019
|
|
Urine biomarkersof tobacco and opium and risk of cancers anad heart disease
|
Research Initiative
|
CDC, FDA
|
|
2020
|
|
US Preventive Services Task Force (USPSTF)
|
Resource Development
|
AHRQ, CDC, CMS, HRSA, IHS, OASH, FDA, SAMHSA
|
NCI
|
2001
|
|
US Public Health Service (USPHS) Physicians Professional Advisory Committee (PPAC)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA
|
NIAID
|
2015
|
|
USDA-HHS Birth to 24 Months ; Pregnant Women Project Federal Expert Group
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NCI, NHLBI, NICHD, NIDDK, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ODP
|
2012
|
|
Vaccines and Related Blood Products Advisory Committee (VRBPAC)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCATS
|
2018
|
|
Validation study of the electrophilic allergen screening assay
|
Research Initiative
|
FDA
|
|
2017
|
|
Virology Interest Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
NHLBI, NIAID, NIAMS, NICHD, NIDCR, NIDDK, NIMH, NINDS
|
1994
|
|
Vision Research Collaborative
|
Research Initiative
|
FDA
|
NEI
|
2020
|
|
White House Gender Policy Council: Science & Technology Interagency Working Group
|
Committee, Advisory Group, or Work Group
|
OASH, FDA
|
NICHD, NCI
|
|
|
World Health Organization Pediatric Antiretroviral Drug Optimization (PADO)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
|
|
|